Emerging Approaches to GPCR Ligand Screening for Drug Discovery

Trends in Molecular Medicine

Volumn 21, Issue 11, 2015, Pages 687-701

  Kumari, Punita ^a   Ghosh, Eshan ^a   Shukla, Arun K ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY KANPUR   (India)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; LIGAND; MOLECULAR LIBRARY;

ALLOSTERISM; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; DRUG DESIGN; DRUG DEVELOPMENT; HIGH THROUGHPUT SCREENING; HUMAN; LIGAND BINDING; REVIEW; SENSOR; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; METABOLISM; MOLECULAR LIBRARY; PHARMACOLOGY; PROCEDURES;

ANIMALS; DRUG DISCOVERY; HUMANS; LIGANDS; MODELS, MOLECULAR; RECEPTORS, G-PROTEIN-COUPLED; SMALL MOLECULE LIBRARIES;

EID: 84947581439     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2015.09.002     Document Type: Review

References (100)

1. Pierce K.L., et al. Seven-transmembrane receptors. Nat. Rev. Mol. Cell Biol. 2002, 3:639-650.
2. Bockaert J., Pin J.P. Molecular tinkering of G protein-coupled receptors: an evolutionary success. EMBO J. 1999, 18:1723-1729.
3. Heng B.C., et al. An overview of the diverse roles of G-protein coupled receptors (GPCRs) in the pathophysiology of various human diseases. Biotechnol. Adv. 2013, 31:1676-1694.
4. Pierce K.L., Lefkowitz R.J. Classical and new roles of beta-arrestins in the regulation of G-protein-coupled receptors. Nat. Rev. Neurosci. 2001, 2:727-733.
5. Kang D.S., et al. Role of beta-arrestins and arrestin domain-containing proteins in G protein-coupled receptor trafficking. Curr. Opin. Cell Biol. 2014, 27:63-71.
6. DeWire S.M., et al. Beta-arrestins and cell signaling. Annu. Rev. Physiol. 2007, 69:483-510.
7. Ma P., Zemmel R. Value of novelty?. Nat. Rev. Drug Discov. 2002, 1:571-572.
8. Overington J.P., et al. How many drug targets are there?. Nat. Rev. Drug Discov. 2006, 5:993-996.
9. Violin J.D., Lefkowitz R.J. Beta-arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol. Sci. 2007, 28:416-422.
10. Whalen E.J., et al. Therapeutic potential of beta-arrestin- and G protein-biased agonists. Trends Mol. Med. 2011, 17:126-139.
11. Takakura H., et al. Cell-based assays and animal models for GPCR drug screening. Methods Mol. Biol. 2015, 1272:257-270.
12. Lin C., et al. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect. Disord. Drug Targets 2006, 6:3-16.
13. Rahuel J., et al. Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chem. Biol. 2000, 7:493-504.
14. Palczewski K., et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 2000, 289:739-745.
15. Evers A., Klebe G. Successful virtual screening for a submicromolar antagonist of the neurokinin-1 receptor based on a ligand-supported homology model. J. Med. Chem. 2004, 47:5381-5392.
16. Evers A., Klabunde T. Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the alpha1A adrenergic receptor. J. Med. Chem. 2005, 48:1088-1097.
17. Evers A., Klebe G. Ligand-supported homology modeling of G-protein-coupled receptor sites: models sufficient for successful virtual screening. Angew. Chem. Int. Ed. Engl. 2004, 43:248-251.
18. Cherezov V., et al. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 2007, 318:1258-1265.
19. Jazayeri A., et al. From G protein-coupled receptor structure resolution to rational drug design. J. Biol. Chem. 2015, 290:19489-19495.
20. Piscitelli C.L., et al. A molecular pharmacologist's guide to GPCR crystallography. Mol. Pharmacol. 2015, 88:536-551.
21. Ghosh E., et al. Methodological advances: the unsung heroes of the GPCR structural revolution. Nat. Rev. Mol. Cell Biol. 2015, 16:69-81.
22. Lee S.M., et al. Structural insights into ligand recognition and selectivity for classes A, B, and C GPCRs. Eur. J. Pharmacol. 2015, Published online May 14, 2105. 10.1016/j.ejphar.2015.05.013.
23. Katritch V., et al. Structure-function of the G protein-coupled receptor superfamily. Annu. Rev. Pharmacol. Toxicol. 2013, 53:531-556.
24. Hollenstein K., et al. Insights into the structure of class B GPCRs. Trends Pharmacol. Sci. 2014, 35:12-22.
25. Bennett K.A., et al. Structures of mGluRs shed light on the challenges of drug development of allosteric modulators. Curr. Opin. Pharmacol. 2015, 20:1-7.
26. Ghosh E., et al. SnapShot: GPCR-ligand interactions. Cell 2014, 159:1712.
27. Xu F., et al. Structure of an agonist-bound human A2A adenosine receptor. Science 2011, 332:322-327.
28. Jaakola V.P., et al. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 2008, 322:1211-1217.
29. Rasmussen S.G., et al. Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor. Nature 2011, 469:175-180.
30. Kruse A.C., et al. Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature 2013, 504:101-106.
31. Haga K., et al. Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. Nature 2012, 482:547-551.
32. Huang W., et al. Structural insights into micro-opioid receptor activation. Nature 2015, 524:315-321.
33. Manglik A., et al. Crystal structure of the micro-opioid receptor bound to a morphinan antagonist. Nature 2012, 485:321-326.
34. Shoichet B.K., Kobilka B.K. Structure-based drug screening for G-protein-coupled receptors. Trends Pharmacol. Sci. 2012, 33:268-272.
35. Congreve M., et al. Structure-based drug design for G protein-coupled receptors. Prog. Med. Chem. 2014, 53:1-63.
36. Kolb P., et al. Structure-based discovery of beta2-adrenergic receptor ligands. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:6843-6848.
37. Wacker D., et al. Conserved binding mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography. J. Am. Chem. Soc. 2010, 132:11443-11445.
38. Rodriguez D., et al. Molecular docking screening using agonist-bound GPCR structures: probing the A2A adenosine receptor. J. Chem. Inf. Model. 2015, 55:550-563.
39. Katritch V., et al. Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. J. Med. Chem. 2010, 53:1799-1809.
40. Langmead C.J., et al. Identification of novel adenosine A(2A) receptor antagonists by virtual screening. J. Med. Chem. 2012, 55:1904-1909.
41. Congreve M., et al. Discovery of 1,2,4-triazine derivatives as adenosine A(2A) antagonists using structure-based drug design. J. Med. Chem. 2012, 55:1898-1903.
42. de Graaf C., et al. Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor. J. Med. Chem. 2011, 54:8195-8206.
43. Vass M., et al. Virtual fragment screening on GPCRs: a case study on dopamine D3 and histamine H4 receptors. Eur. J. Med. Chem. 2014, 77:38-46.
44. Lane J.R., et al. Structure-based ligand discovery targeting orthosteric and allosteric pockets of dopamine receptors. Mol. Pharmacol. 2013, 84:794-807.
45. Carlsson J., et al. Ligand discovery from a dopamine D3 receptor homology model and crystal structure. Nat. Chem. Biol. 2011, 7:769-778.
46. Kruse A.C., et al. Muscarinic receptors as model targets and antitargets for structure-based ligand discovery. Mol. Pharmacol. 2013, 84:528-540.
47. Rodriguez D., et al. Structure-based discovery of selective serotonin 5-HT(1B) receptor ligands. Structure 2014, 22:1140-1151.
48. Negri A., et al. Discovery of a novel selective kappa-opioid receptor agonist using crystal structure-based virtual screening. J. Chem. Inf. Model. 2013, 53:521-526.
49. Mysinger M.M., et al. Structure-based ligand discovery for the protein-protein interface of chemokine receptor CXCR4. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:5517-5522.
50. Rasmussen S.G., et al. Crystal structure of the beta2 adrenergic receptor-Gs protein complex. Nature 2011, 477:549-555.
51. Weiss D.R., et al. Conformation guides molecular efficacy in docking screens of activated beta-2 adrenergic G protein coupled receptor. ACS Chem. Biol. 2013, 8:1018-1026.
52. Reynolds K.A., et al. Identifying conformational changes of the beta(2) adrenoceptor that enable accurate prediction of ligand/receptor interactions and screening for GPCR modulators. J. Comput. Aided Mol. Des. 2009, 23:273-288.
53. Tosh D.K., et al. Optimization of adenosine 5'-carboxamide derivatives as adenosine receptor agonists using structure-based ligand design and fragment screening. J. Med. Chem. 2012, 55:4297-4308.
54. Kruse A.C., et al. Structure and dynamics of the M3 muscarinic acetylcholine receptor. Nature 2012, 482:552-556.
55. Wacker D., et al. Structural features for functional selectivity at serotonin receptors. Science 2013, 340:615-619.
56. Wang C., et al. Structural basis for molecular recognition at serotonin receptors. Science 2013, 340:610-614.
57. Hollenstein K., et al. Structure of class B GPCR corticotropin-releasing factor receptor 1. Nature 2013, 499:438-443.
58. Zhang J., et al. Agonist-bound structure of the human P2Y12 receptor. Nature 2014, 509:119-122.
59. Zhang K., et al. Structure of the human P2Y12 receptor in complex with an antithrombotic drug. Nature 2014, 509:115-118.
60. Zhang D., et al. Two disparate ligand-binding sites in the human P2Y1 receptor. Nature 2015, 520:317-321.
61. Srivastava A., et al. High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875. Nature 2014, 513:124-127.
62. Hanson M.A., et al. Crystal structure of a lipid G protein-coupled receptor. Science 2012, 335:851-855.
63. Navratilova I., et al. Screening for GPCR ligands using surface plasmon resonance. ACS Med. Chem. Lett. 2011, 2:549-554.
64. Navratilova I., Hopkins A.L. Emerging role of surface plasmon resonance in fragment-based drug discovery. Future Med. Chem. 2011, 3:1809-1820.
65. Aristotelous T., et al. Surface plasmon resonance analysis of seven-transmembrane receptors. Methods Enzymol. 2015, 556:499-525.
66. Aristotelous T., et al. Discovery of beta2 adrenergic receptor ligands using biosensor fragment screening of tagged wild-type receptor. ACS Med. Chem. Lett. 2013, 4:1005-1010.
67. Congreve M., et al. Fragment screening of stabilized G-protein-coupled receptors using biophysical methods. Methods Enzymol. 2011, 493:115-136.
68. Christopher J.A., et al. Biophysical fragment screening of the beta1-adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design. J. Med. Chem. 2013, 56:3446-3455.
69. Lundstrom K., et al. Structural genomics on membrane proteins: comparison of more than 100 GPCRs in 3 expression systems. J. Struct. Funct. Genomics 2006, 7:77-91.
70. Shukla A.K., et al. Dimethylsulphoxide as a tool to increase functional expression of heterologously produced GPCRs in mammalian cells. FEBS Lett. 2006, 580:4261-4265.
71. Kobilka B.K. Amino and carboxyl terminal modifications to facilitate the production and purification of a G protein-coupled receptor. Anal. Biochem. 1995, 231:269-271.
72. Chae P.S., et al. Maltose-neopentyl glycol (MNG) amphiphiles for solubilization, stabilization and crystallization of membrane proteins. Nat. Methods 2010, 7:1003-1008.
73. Christopher J., et al. Fragment and structure-based drug discovery for a class C GPCR: discovery of the mGlu5 negative allosteric modulator HTL14242 (3-chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). J. Med. Chem. 2015, 58:6653-6664.
74. Wisler J.W., et al. Recent developments in biased agonism. Curr. Opin. Cell Biol. 2014, 27:18-24.
75. Luttrell L.M., Minireview: More than just a hammer: ligand 'bias' and pharmaceutical discovery. Mol. Endocrinol. 2014, 28:281-294.
76. Kenakin T., Christopoulos A. Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat. Rev. Drug Discov. 2013, 12:205-216.
77. Shukla A.K., et al. Emerging structural insights into biased GPCR signaling. Trends Biochem. Sci. 2014, 39:594-602.
78. Warne T., et al. Crystal structures of a stabilized beta1-adrenoceptor bound to the biased agonists bucindolol and carvedilol. Structure 2012, 20:841-849.
79. Wu H., et al. Structure of a class C GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator. Science 2014, 344:58-64.
80. Dore A.S., et al. Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain. Nature 2014, 511:557-562.
81. Salchow K., et al. A common intracellular allosteric binding site for antagonists of the CXCR2 receptor. Br. J. Pharmacol. 2010, 159:1429-1439.
82. Bradley M.E., et al. SB265610 is an allosteric, inverse agonist at the human CXCR2 receptor. Br. J. Pharmacol. 2009, 158:328-338.
83. Wang D., et al. Amyloid beta peptide-(1-42) induces internalization and degradation of beta2 adrenergic receptors in prefrontal cortical neurons. J. Biol. Chem. 2011, 286:31852-31863.
84. Coureuil M., et al. Meningococcus Hijacks a beta2-adrenoceptor/beta-Arrestin pathway to cross brain microvasculature endothelium. Cell 2010, 143:1149-1160.
85. Walter S., et al. Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients. J. Pharmacol. Exp. Ther. 2013, 346:229-240.
86. Bell G., et al. A randomized, double-blind, phase 2 study evaluating the safety and efficacy of AMG 416 for the treatment of secondary hyperparathyroidism in hemodialysis patients. Curr. Med. Res. Opin. 2015, 31:943-952.
87. Webb D.R., et al. Opportunities for functional selectivity in GPCR antibodies. Biochem. Pharmacol. 2013, 85:147-152.
88. Wallukat G., Schimke I. Agonistic autoantibodies directed against G-protein-coupled receptors and their relationship to cardiovascular diseases. Semin. Immunopathol. 2014, 36:351-363.
89. Rossant C.J., et al. Phage display and hybridoma generation of antibodies to human CXCR2 yields antibodies with distinct mechanisms and epitopes. MAbs 2014, 6:1425-1438.
90. Hino T., et al. G-protein-coupled receptor inactivation by an allosteric inverse-agonist antibody. Nature 2012, 482:237-240.
91. Shukla A.K., et al. Antibody fragments for stabilization and crystallization of G protein-coupled receptors and their signaling complexes. Methods Enzymol. 2015, 557:247-258.
92. Kang Y., et al. Crystal structure of rhodopsin bound to arrestin by femtosecond X-ray laser. Nature 2015, 523:561-567.
93. Szollosi E., et al. Cell-based and virtual fragment screening for adrenergic alpha2C receptor agonists. Bioorg. Med. Chem. 2015, 23:3991-3999.
94. Perry S.R., et al. Three homology models of PAR2 derived from different templates: application to antagonist discovery. J. Chem. Inf. Model. 2015, 55:1181-1191.
95. Congreve M., et al. The use of GPCR structures in drug design. Adv. Pharmacol. 2011, 62:1-36.
96. Sabio M., et al. Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Part 2: Identification of active compounds. Bioorg. Med. Chem. Lett. 2008, 18:5391-5395.
97. Sanders M.P., et al. A prospective cross-screening study on G-protein-coupled receptors: lessons learned in virtual compound library design. J. Med. Chem. 2012, 55:5311-5325.
98. Carlsson J., et al. Structure-based discovery of A2A adenosine receptor ligands. J. Med. Chem. 2010, 53:3748-3755.
99. van Westen G.J., et al. Identifying novel adenosine receptor ligands by simultaneous proteochemometric modeling of rat and human bioactivity data. J. Med. Chem. 2012, 55:7010-7020.
100. Chen D., et al. Fragment screening of GPCRs using biophysical methods: identification of ligands of the adenosine A(2A) receptor with novel biological activity. ACS Chem. Biol. 2012, 7:2064-2073.